Kiora Pharmaceuticals, Inc. (KPRX)

NASDAQ: KPRX · IEX Real-Time Price · USD
0.694
+0.104 (17.66%)
At close: Feb 26, 2024, 4:00 PM
0.707
+0.013 (1.92%)
After-hours: Feb 26, 2024, 7:57 PM EST
17.66%
Market Cap 4.53M
Revenue (ttm) n/a
Net Income (ttm) -13.27M
Shares Out 7.69M
EPS (ttm) 0.83
PE Ratio 0.84
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,092,867
Open 0.581
Previous Close 0.590
Day's Range 0.581 - 0.734
52-Week Range 0.462 - 5.250
Beta -0.36
Analysts Strong Buy
Price Target 2.00 (+188.31%)
Earnings Date Mar 5, 2024

About KPRX

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Brian M. Strem Ph.D.
Employees 12
Stock Exchange NASDAQ
Ticker Symbol KPRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for KPRX stock is "Strong Buy." The 12-month stock price forecast is $2.0, which is an increase of 188.31% from the latest price.

Price Target
$2.0
(188.31% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

$15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million ...

26 days ago - Newsfile Corp

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties

Kiora to webcast investor conference call at 5:30 pm today; details below Encinitas, California and Clermont-Ferrand, France--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ:...

26 days ago - Newsfile Corp

AllianceBernstein Launches 5 New Active ETFs

On the heels of crossing the $1 billion threshold in active ETF AUM, AllianceBernstein has launched five active exchange-traded funds today: two on the New York Stock Exchange, and three on the Nasdaq...

Other symbols: BUFCCPLSEYEGTAFLTAFM
2 months ago - ETF Trends

AllianceBernstein Launches Five New Active ETFs

Lineup includes one Buffered product and four Fixed Income products in AB's ETF suite NASHVILLE, Tenn. , Dec. 13, 2023 /PRNewswire/ -- AllianceBernstein Holding L.P.

Other symbols: ABBUFCCPLSEYEGTAFLTAFM
2 months ago - PRNewsWire

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - November 9, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its third quarter 2023 financial results and is provi...

3 months ago - Newsfile Corp

AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

Topline Phase I/II First-in-Human Results Presented at AAO 2023 Significant improvement in visual field, in concordance with trended improvements in visual acuity and functional vision Functional MRI ...

4 months ago - Newsfile Corp

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

Encinitas, California--(Newsfile Corp. - October 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation from the Lytham Partners Fall 2023 Investo...

4 months ago - Newsfile Corp

Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - October 3, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) has received Investigational New Drug Application approval in Australia to enroll up to six additional ...

5 months ago - Newsfile Corp

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Encinitas, California--(Newsfile Corp. - September 21, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced that its board of directors has appointed Praveen Tyle, PhD, who currently serves as...

5 months ago - Newsfile Corp

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - September 18, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the completion of the final patient's last endpoint evaluation from the ABACUS study...

5 months ago - Newsfile Corp

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

Encinitas, California--(Newsfile Corp. - September 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from the ABACUS study of KIO-301 in patient...

5 months ago - Newsfile Corp

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27

Encinitas, California--(Newsfile Corp. - September 1, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that the Company's Special Meeting of Stockholders (the "S...

6 months ago - Newsfile Corp

Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases

Live Event to be Held Thursday, August 31, at 7:30 pm Eastern Time Encinitas, California--(Newsfile Corp. - August 29, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites you to participate in a webi...

6 months ago - Newsfile Corp

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis

Encinitas, California--(Newsfile Corp. - August 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has been granted U.S. (Patent # 11,730,716) and Eur...

6 months ago - Newsfile Corp

Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program

Encinitas, California--(Newsfile Corp. - August 22, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotechnology company developing novel therapies for the treatment of ophthalmi...

6 months ago - Newsfile Corp

Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Encinitas, California--(Newsfile Corp. - August 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) welcomes investors to watch the Company's online presentation from the H.C. Wainwright 3rd Annual Ophth...

6 months ago - Newsfile Corp

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress

Positive Preliminary Data Reported in Q2 Demonstrated Clear Clinical Proof-of-Concept of KIO-301 in the Ongoing Phase 1 Study in Retinitis Pigmentosa Supporting Advancement to Planned Higher Doses wit...

7 months ago - Newsfile Corp

Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment

Encinitas, California--(Newsfile Corp. - August 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage ophthalmic pharmaceutical company developing novel therapeutics for patients wit...

7 months ago - Newsfile Corp

Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors

Encinitas, California--(Newsfile Corp. - August 1, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has appointed Carmine Stengone as an independent member to the Company's board of directors. Steng...

7 months ago - Newsfile Corp

Kiora Pharmaceuticals Receives $1.2 Million in Research Tax Credits to Advance the Treatment of Ophthalmic Disease

Encinitas, California--(Newsfile Corp. - July 5, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its wholly owned subsidiaries have received, in aggregate, $1.2 million related to researc...

8 months ago - Newsfile Corp

Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201

Amendment eliminates $4.75M in near-term milestones Kiora would have owed to Sentrx Sentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veter...

9 months ago - Newsfile Corp

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Encinitas, California--(Newsfile Corp. - June 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its President & CEO, Brian Strem, Ph.D., will participate in two upcoming investor confer...

9 months ago - Newsfile Corp

Kiora Pharmaceuticals Announces Closing of $6.3 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

Encinitas, California--(Newsfile Corp. - June 6, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross ...

9 months ago - Newsfile Corp

Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering

Encinitas, California--(Newsfile Corp. - June 2, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross ...

9 months ago - Newsfile Corp

Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments

Encinitas, California--(Newsfile Corp. - May 9, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug devel...

10 months ago - Newsfile Corp